Note: Intro -- Preface -- Introduction -- Contents -- Part I: Future Technological Advances to Elucidate the Structures and Functions of Glycans -- Foreword -- Chapter 1: Structural Analysis of Glycans (Analytical and Detection Methods) -- 1.1 Liquid Chromatography/Mass Spectrometry (LC-MS) -- 1.2 Ion Mobility-Mass Spectrometry(IM-MS) -- 1.3 Current Status and Future of the Automated Glycan Analysis Technologies -- 1.4 Glycoproteomics -- 1.5 O-Glycome Analysis of Glycoproteins -- 1.6 Glycolipidomics -- 1.7 Glycometabolome -- 1.8 Glyco-array -- 1.9 Glycolipid Array -- 1.10 Lectin Blotting -- 1.11 Lectin Engineering -- 1.12 Recognition of iPS/ES Cells by Glycan-Binding Antibodies -- 1.13 The EMARS Method -- References -- References for Section 1.1 -- References for Section 1.2 -- References for Section 1.3 -- References for Section 1.4 -- References for Section 1.5 -- References for Section 1.6 -- References for Section 1.7 -- References for Section 1.8 -- References for Section 1.9 -- References for Section 1.10 -- References for Section 1.11 -- References for Section 1.12 -- References for Section 1.13 -- Chapter 2: Structural Biology of Glycans -- 2.1 Study of Glycan Structure and Its Recognition Mechanism by Cryo-electron Microscope Single Particle Analysis -- 2.2 Conformational Analysis of Oligosaccharides -- 2.3 Conformational Analysis of Glycans -- 2.4 Computational Science (Supercomputer) and AI (Artificial Intelligence) -- 2.5 Structural Study of Proteins in the Glycoscience Field -- 2.6 Structural Analysis of Sugar Related Proteins -- 2.7 Simulation and Imaging of Membranes -- 2.8 Simulation/Imaging of Membranes -- 2.9 Molecular Imaging of Cells and Organisms Using Labeled Glycans -- 2.10 Diagnosis and Imaging Using Labeled Glycans in Cells and Organisms. , 2.11 Glycoconjugates and Glycoclusters as New Drug Delivery Molecules for In Vivo Molecular Imaging and Theranostics -- 2.12 Imaging Mass Spectrometry (IMS) -- References -- References for Section 2.1 -- References for Section 2.2 -- References for Section 2.3 -- References for Section 2.4 -- References for Section 2.5 -- References for Section 2.6 -- References for Section 2.7 -- References for Section 2.8 -- References for Section 2.9 -- References for Section 2.10 -- References for Section 2.11 -- References for Section 2.12 -- Chapter 3: Chemical and Enzymatic Synthesis and Production of Glycans -- 3.1 Synthetic Glycans -- 3.2 Recent Progress and Perspective on Automated Synthesis of Oligosaccharides -- 3.3 New Synthetic Methods for Standard Glycans: Glycoproteins -- 3.4 New Synthetic Methods for Standard Glycans: N-Glycans -- 3.5 New Synthetic Methods for Standard Glycans: Glycolipids -- 3.6 New Synthetic Methods for Standard Glycans: Neo-Glycoconjugates -- 3.7 New Synthetic Methods of Standard Glycans: GPI -- 3.8 New Synthetic Methods for Standard Glycans: GAG -- 3.9 New Synthetic Methods of Standard Glycans: Glycopeptides -- References -- References for Section 3.1 -- References for Section 3.2 -- References Section for 3.3 -- References for Section 3.4 -- References for Section 3.5 -- References Section for 3.6 -- References Section for 3.7 -- References Section for 3.8 -- References Section for 3.9 -- Chapter 4: Technologies to Elucidate Functions of Glycans -- 4.1 Genetically Modified Mice: Glycolipids -- 4.2 Genetically Modified Mouse:Glycolipids -- 4.3 Genetically Modified Mice: Glycosphingolipid Synthases -- 4.4 Genetically Modified Mice: Glycoproteins -- 4.5 Genetically Modified Mice: Glycosaminoglycans (GAGs) -- 4.6 Mice with Genetic Mutations in the Glycosaminoglycan Biosynthetic Pathway -- 4.7 Drosophila melanogaster. , 4.8 Caenorhabditis elegans, the Nematode Worm -- 4.9 Medaka and Zebrafish (Small Fish as Experimental Models) -- 4.10 Gene Modification: Small Fish (Zebrafish and Medaka) -- 4.11 Genetically Modified Small Fish (Zebrafish and Medaka) -- 4.12 Genetic Modification: Small Fish (Zebrafish and Medaka) -- 4.13 Plant and Glycans -- 4.14 Plant and Glycan -- 4.15 Genetic Modification of Yeast -- 4.16 Chemical Library -- References -- References for Section 4.1 -- References for Section 4.2 -- References for Section 4.3 -- References for Section 4.4 -- References for Section 4.5 -- References for Section 4.6 -- References for Section 4.7 -- References for Section 4.8 -- References for Section 4.9 -- References for Section 4.10 -- References for Section 4.11 -- References for Section 4.12 -- References for Section 4.13 -- References for Section 4.14 -- References for Section 4.15 -- References for Section 4.16 -- Part II: Glycans and Biopharmaceuticals -- Foreword -- Chapter 5: Antibody Pharmaceuticals -- 5.1 Biosimilar/Follow-On and Biobetter Biologics -- 5.2 Quality Evaluation of Glycoprotein Products Using Glycoprotein with Homogeneous Glycans -- References -- References for Section 5.1 -- References for Section 5.2 -- Chapter 6: Standard Glycan Library -- 1.1 Human-Type Glycan Library -- References -- Chapter 7: Mass Production in Silk Worm and Yeast -- 7.1 Glycoprotein Production with Yeast -- 7.2 Mass Production of Glycoproteins Using Silkworms -- References -- References for Section 7.1 -- References for Section 7.2 -- Chapter 8: Glycoengineering -- 8.1 Chemistry-Based Engineering -- 8.2 Tools for Glycoengineering: Key Enzymes -- 8.3 Therapeutic Antibody (ADCC) -- 8.4 Antibody-Drug Conjugates (ADCs) -- 8.5 Lectin-Drug Conjugates (LDCs) -- 8.6 Polysaccharide-Based Drug Delivery System: A New Approach Involving Use of β-Glucan/DNA Complexes. , 8.7 Remodeling of Glycoantigens in Bio-Artificial Organs/Tissues -- 8.8 Therapeutic Potential of Carbohydrate Mimetic Peptides Composed of D-Type Amino Acids -- References -- References for Section 8.1 -- References for Section 8.2 -- References for Section 8.3 -- References for Section 8.4 -- References for Section 8.5 -- References for Section 8.6 -- References for Section 8.7 -- References for Section 8.8 -- Chapter 9: Glycomimetics -- 9.1 Selectin Inhibitors -- 9.2 Development of Siglec Regulators -- 9.3 Galectin Inhibitors -- 9.4 Inhibitors of Glycolsyltransferases -- References -- References for Section 9.1 -- References for Section 9.2 -- References for Section 9.3 -- References for Section 9.4 -- Chapter 10: Glycan Vaccine -- 10.1 Microbial Glycans and Immune-Response -- 10.2 Pathogen-Derived Glycolipids -- 10.3 Carbohydrate-Based Vaccines -- References -- References for Section 10.1 -- References for Section 10.2 -- References for Section 10.3 -- Part III: Sugar Chains (Glycans) Involved in Medical Science and Medical Care -- Foreword -- Chapter 11: Glycan Function in Development and its Regulation -- 11.1 Roles of Glycans in Development, Evolution and Stem Cells -- 11.2 A Characteristic Glycan Profile of Stem Cells -- 11.3 Epigenetics of Glyco-Genes -- 11.4 Epigenetic Regulation of Glyco-Genes -- 11.5 Posttranscriptional Regulation of Glycan Expression by MicroRNA -- 11.6 Drug Resistance -- 11.7 Secretion and Uptake of Exosomes Via Glycan -- References -- References for Section 11.1 -- References for Section 11.2 -- References for Section 11.3 -- References for Section 11.4 -- References for Section 11.5 -- References for Section 11.6 -- References for Section 11.7 -- Chapter 12: Glycans in Nervous System -- 12.1 Schizophrenia (Polysialic Acid) -- 12.2 Schizophrenia -- 12.3 Spinal Cord Injury -- 12.4 Microglia -- References. , References for Section 12.1 -- References for Section 12.2 -- References for Section 12.3 -- References for Section 12.4 -- Chapter 13: Glycans in Osseous Tissue and Articulation -- 13.1 Bone Diseases -- 13.2 Arthritis -- References -- References for Section 13.1 -- References for Section 13.2 -- Chapter 14: Glycans in Infection and Immunity -- 14.1 Influenza Virus -- 14.2 Recent Research Topics of Influenza -- 14.3 Pathogens and GPI Anchors -- 14.4 Sugar Chain-Mediated Interaction Between Microbes and Higher Animals -- 14.5 Current Status and Future Directions of Study on Glycosylation for Gut Microbiota and the Mucosal Immune Network -- 14.6 Carbohydrate-Mediated Interactions Between Microbial and Higher Animal Cells (Fungi) -- 14.7 Plasmodium and Protozoa in General -- 14.8 GPI Anchor Deficiencies -- 14.9 Defense Mechanism -- 14.10 Siglecs -- 14.11 Collectins -- 14.12 Autoimmune Disease, Immunosuppressive Drugs -- References -- References for Section 14.1 -- References for Section 14.2 -- References for Section 14.3 -- References for Section 14.4 -- References for Section 14.5 -- References for Section 14.6 -- References for Section 14.7 -- References for Section 14.8 -- References for Section 14.9 -- References for Section 14.10 -- References for Section 14.11 -- References for Section 14.12 -- Chapter 15: Next Generation Medical Care -- 15.1 Roles of Glycoscience in Development of Personalized Medicine and Rational Medical Practices -- 15.2 Health Monitoring -- 15.3 Presymptomatic Diagnosis, Particularly for Dementia, Cancer and Hydrocephalous -- 15.4 Core Technologies for Elucidating the Role of Glycans in Disease -- References -- References for Section 15.1 -- References for Section 15.2 -- References for Section 15.3 -- References for Section 15.4 -- Chapter 16: Life-Style Related Disease and Aging -- 16.1 Diabetes -- 16.2 Obesity. , 16.3 Chronic Obstructive Pulmonary Disease(COPD).